Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

Abstract

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.

What is claimed is: 
     
         1 . A method of stimulating gastrointestinal motility comprising administering to a subject suffering from at least two disorders caused by gastrointestinal dysmotility an effective amount of a compound having any of the following structures: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein the compound is administered orally. 
     
     
         3 . The method of  claim 1 , wherein the compound is administered parenterally. 
     
     
         4 . The method of  claim 1 , wherein the compound is administered intracranially. 
     
     
         5 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         6 . The method of  claim 1 , wherein the subject is a human. 
     
     
         7 . The method of  claim 1 , wherein the compound is co-administered with an additional agent useful for stimulating gastrointestinal motility. 
     
     
         8 . The method of  claim 1 , wherein the disorders caused by gastrointestinal dysmotility are selected from the group consisting of postoperative ileus, gastroparesis, idiopathic gastroparesis, diabetic gastroparesis, post-surgical gastroparesis, gastric stasis, opioid-induced bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, emesis, constipation-predominant irritable bowel syndrome (IBS), delayed gastric emptying, gastroesophageal reflux disease (GERD), gastric ulcers, and Crohn's disease. 
     
     
         9 . The method of  claim 1 , wherein one of the disorders is postoperative ileus. 
     
     
         10 . The method of  claim 1 , wherein one of the disorders is gastric statis. 
     
     
         11 . The method of  claim 1 , wherein one of the disorders is diabetic gastroparesis or post-surgical gastroparesis. 
     
     
         12 . The method of  claim 1 , wherein the disorders are postoperative ileus and opioid-induced bowel dysfunction. 
     
     
         13 . The method of  claim 1 , wherein the disorders are post-surgical gastroparesis and opioid-induced bowel dysfunction. 
     
     
         14 . The method of  claim 1 , wherein at least two disorders occur concurrently. 
     
     
         15 . The method of  claim 1 , wherein at least two disorders occur sequentially. 
     
     
         16 . The method of  claim 1 , wherein a dose level of the compound having the structure shown in  claim 1  to treat the at least two disorders is an equivalent dose level to that required to treat a single disorder caused by gastrointestinal dysmotility. 
     
     
         17 . The method of  claim 1 , wherein the dose level of the compound having the structure shown in  claim 1  is in a range of about 50-150% of a dose level required to treat a single disorder caused by gastrointestinal dysmotility.